Posted by Michael Wonder on 02 Feb 2022
Olaparib a 'no go' for patients with breast cancer in England
2 February 2022 - Olaparib has been approved to treat patients with BRCA mutation positive HER2 negative metastatic breast cancer after chemotherapy.
NICE is unable to make a recommendation on the use of olaparib (Lynparza) for the treatment of patients BRCA mutation-positive HER2 negative metastatic breast cancer after chemotherapy because AstraZeneca did not provide an evidence submission.
